Search

Your search keyword '"Hovi, L."' showing total 255 results
Start Over Author "Hovi, L."
255 results on '"Hovi, L."'

11. Restoration of ovarian function after chemotherapy for osteosarcoma. (Original Article)

Author

Wikstrom, A.M., Hovi, L., Dunkel, L., and Saarinen-Pihkala, U.M.

Subjects
Osteosarcoma -- Care and treatment, Cancer survivors -- Research, Methodology
Abstract

Aim: To evaluate ovarian function after modern intensive multi-agent chemotherapy for osteosarcoma given during childhood or adolescence. Methods: After discontinuation of treatment, 10 female osteosarcoma survivors were followed up for […]

Published
2003

16. Erratum: Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol (Leukemia (2016) 30 5 (1184-1187))

Author

Driessen E. M. C., Driessen, E, de Lorenzo, P, Campbell, M, Felice, M, Ferster, A, Hann, I, Vora, A, Hovi, L, Escherich, G, Li, C, Mann, G, Leblanc, T, Locatelli, F, Biondi, A, Rubnitz, J, Schrappe, M, Silverman, L, Stary, J, Suppiah, R, Szczepanski, T, Valsecchi, M, Pieters, R, Driessen E. M. C., de Lorenzo P., Campbell M., Felice M., Ferster A., Hann I., Vora A., Hovi L., Escherich G., Li C. K., Mann G., Leblanc T., Locatelli F., Biondi A., Rubnitz J., Schrappe M., Silverman L., Stary J., Suppiah R., Szczepanski T., Valsecchi M., Pieters R., Driessen E. M. C., Driessen, E, de Lorenzo, P, Campbell, M, Felice, M, Ferster, A, Hann, I, Vora, A, Hovi, L, Escherich, G, Li, C, Mann, G, Leblanc, T, Locatelli, F, Biondi, A, Rubnitz, J, Schrappe, M, Silverman, L, Stary, J, Suppiah, R, Szczepanski, T, Valsecchi, M, Pieters, R, Driessen E. M. C., de Lorenzo P., Campbell M., Felice M., Ferster A., Hann I., Vora A., Hovi L., Escherich G., Li C. K., Mann G., Leblanc T., Locatelli F., Biondi A., Rubnitz J., Schrappe M., Silverman L., Stary J., Suppiah R., Szczepanski T., Valsecchi M., and Pieters R.

Abstract

This corrects the article DOI: 10.1038/leu.2015.246.

Published
2017

24. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

Author

Driessen, E. M. C., De Lorenzo, P., Campbell, M., Felice, M., Ferster, A., Hann, I., Vora, A., Hovi, L., Escherich, G., Li, C. K., Mann, G., Leblanc, T., Locatelli, Franco, Biondi, A., Rubnitz, J., Schrappe, M., Silverman, L., Stary, J., Suppiah, R., Szczepanski, T., Valsecchi, M., Pieters, R., Locatelli F. (ORCID:0000-0002-7976-3654), Driessen, E. M. C., De Lorenzo, P., Campbell, M., Felice, M., Ferster, A., Hann, I., Vora, A., Hovi, L., Escherich, G., Li, C. K., Mann, G., Leblanc, T., Locatelli, Franco, Biondi, A., Rubnitz, J., Schrappe, M., Silverman, L., Stary, J., Suppiah, R., Szczepanski, T., Valsecchi, M., Pieters, R., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

NO ABSTRACT

Published
2016

25. Corrigenda: Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol (Leukemia, (2016) 30, (1184-1187), 10.1038/leu.2015.246)

Author

Driessen, E. M. C., de Lorenzo, P., Campbell, M., Felice, M., Ferster, A., Hann, I., Vora, A., Hovi, L., Escherich, G., Li, C. K., Mann, G., Leblanc, T., Locatelli, Franco, Biondi, A., Rubnitz, J., Schrappe, M., Silverman, L., Stary, J., Suppiah, R., Szczepanski, T., Valsecchi, M., Pieters, R., Locatelli F. (ORCID:0000-0002-7976-3654), Driessen, E. M. C., de Lorenzo, P., Campbell, M., Felice, M., Ferster, A., Hann, I., Vora, A., Hovi, L., Escherich, G., Li, C. K., Mann, G., Leblanc, T., Locatelli, Franco, Biondi, A., Rubnitz, J., Schrappe, M., Silverman, L., Stary, J., Suppiah, R., Szczepanski, T., Valsecchi, M., Pieters, R., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Correction to: Leukemia (2016) 30, 1184–1187; doi:10.1038/leu.2015.246 Following the publication of this article the authors noted that the labels in Figures 1b and d have been switched. The correct labels in Figure 1b are; mixed lineage leukemia rearranged (MLL rearranged; dotted line) and unknown (thin solid line). In Figure 1d the correct labels are; bone marrow involvement (BM involv; dotted line) and isolated extramedullary (Isolated Ext; thin solid line). The authors wish to apologize for any inconvenience caused. (Figure Presented).

Published
2016

26. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

Author

Driessen, E, de Lorenzo, P, Campbell, M, Felice, M, Ferster, A, Hann, I, Vora, A, Hovi, L, Escherich, G, Li, C, Mann, G, Leblanc, T, Locatelli, F, Biondi, A, Rubnitz, J, Schrappe, M, Silverman, L, Stary, J, Suppiah, R, Szczepanski, T, Valsecchi, M, Pieters, R, Driessen, E, de Lorenzo, P, Campbell, M, Felice, M, Ferster, A, Hann, I, Vora, A, Hovi, L, Escherich, G, Li, C, Mann, G, Leblanc, T, Locatelli, F, Biondi, A, Rubnitz, J, Schrappe, M, Silverman, L, Stary, J, Suppiah, R, Szczepanski, T, Valsecchi, M, and Pieters, R

Published
2016

27. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

Author

Driessen, E M C, primary, de Lorenzo, P, additional, Campbell, M, additional, Felice, M, additional, Ferster, A, additional, Hann, I, additional, Vora, A, additional, Hovi, L, additional, Escherich, G, additional, Li, C K, additional, Mann, G, additional, Leblanc, T, additional, Locatelli, F, additional, Biondi, A, additional, Rubnitz, J, additional, Schrappe, M, additional, Silverman, L, additional, Stary, J, additional, Suppiah, R, additional, Szczepanski, T, additional, Valsecchi, M, additional, and Pieters, R, additional

Published
2015
Full Text
View/download PDF

29. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia

Author

Lönnerholm, G, Valsecchi, M, De Lorenzo, P, Schrappe, M, Hovi, L, Campbell, M, Mann, G, Janka Schaub, G, Li, C, Stary, J, Hann, I, Pieters, R, Pieters, R., VALSECCHI, MARIA GRAZIA, Lönnerholm, G, Valsecchi, M, De Lorenzo, P, Schrappe, M, Hovi, L, Campbell, M, Mann, G, Janka Schaub, G, Li, C, Stary, J, Hann, I, Pieters, R, Pieters, R., and VALSECCHI, MARIA GRAZIA

Abstract

Interfant-99 was an international collaborative treatment protocol for infants with acute lymphoblastic leukemia (ALL).

Published
2009

30. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol

Author

van der Linden, M, Valsecchi, M, De Lorenzo, P, Möricke, A, Janka, G, Leblanc, T, Felice, M, Biondi, A, Campbell, M, Hann, I, Rubnitz, J, Stary, J, Szczepanski, T, Vora, A, Ferster, A, Hovi, L, Silverman, L, Pieters, R, van der Linden, MH, Leblanc, TM, BIONDI, ANDREA, Rubnitz, JE, Silverman, LB, Pieters, R., VALSECCHI, MARIA GRAZIA, van der Linden, M, Valsecchi, M, De Lorenzo, P, Möricke, A, Janka, G, Leblanc, T, Felice, M, Biondi, A, Campbell, M, Hann, I, Rubnitz, J, Stary, J, Szczepanski, T, Vora, A, Ferster, A, Hovi, L, Silverman, L, Pieters, R, van der Linden, MH, Leblanc, TM, BIONDI, ANDREA, Rubnitz, JE, Silverman, LB, Pieters, R., and VALSECCHI, MARIA GRAZIA

Abstract

Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P < .001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487.

Published
2009

31. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial

Author

Pieters, R, Schrappe, M, De Lorenzo, P, Hann, I, De Rossi, G, Felice, M, Hovi, L, Leblanc, T, Szczepanski, T, Ferster, A, Janka, G, Rubnitz, J, Silverman, L, Stary, J, Campbell, M, Li, C, Mann, G, Suppiah, R, Biondi, A, Vora, A, Valsecchi, M, LeBlanc, T, Li, CK, BIONDI, ANDREA, VALSECCHI, MARIA GRAZIA, Pieters, R, Schrappe, M, De Lorenzo, P, Hann, I, De Rossi, G, Felice, M, Hovi, L, Leblanc, T, Szczepanski, T, Ferster, A, Janka, G, Rubnitz, J, Silverman, L, Stary, J, Campbell, M, Li, C, Mann, G, Suppiah, R, Biondi, A, Vora, A, Valsecchi, M, LeBlanc, T, Li, CK, BIONDI, ANDREA, and VALSECCHI, MARIA GRAZIA

Abstract

Background Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children. We initiated an international study to investigate the effects of a new hybrid treatment protocol with elements designed to treat both acute lymphoblastic: leukaemia and acute myeloid leukaemia, and to identify any prognostic factors for outcome in infants. We also did a randomised trial to establish the value of a late intensification course. Methods Patients aged 0-12 months were enrolled by 17 study groups in 22 countries between 1999 and 2005. Eligible patients were stratified for risk according to their peripheral blood response to a 7-day prednisone prophase, and then given a hybrid regimen based on the standard protocol for acute lymphoblastic leukaemia, with some elements designed for treatment of acute myeloid leukaemia. Before the maintenance phase, a subset of patients in complete remission were randomly assigned to receive either standard treatment or a more intensive chemotherapy course with high-dose cytarabine and methotrexate. The primary outcomes were event-free survival (EFS) for the initial cohort of patients and disease-free survival (DFS) for the patients randomly assigned to a treatment group. Data were analysed on an intention-to-treat basis. This trial was registered with ClinicalTrials.gov, number NCT 00015873, and at controlled-trials.com, number ISRCTN24251487. Findings In the 482 enrolled patients who underwent hybrid treatment, 260 (58%) were in complete remission at a median follow-up of 38 (range 1-78) months, and EFS at 4 years was 47.0% (SE 2.6, 95% CI 41.9-52.1). Of 445 patients in complete remission after 5 weeks of induction treatment, 191 were randomised: 95 patients to receive a late intensification course, and 96 to a control group. At a median follow-up of 42 (range 1-73) months, 60 patients in the treatment group and 57 controls were disease-free. DFS at 4 years did not diff

Published
2007

32. Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01.

Author

Kaspers, G.J.L., primary, Zimmermann, M., additional, Reinhardt, D., additional, Gibson, B., additional, Tamminga, R., additional, Aleinikova, O., additional, Armendariz, H., additional, Dworzak, M., additional, Ha, S., additional, Hovi, L., additional, Maschan, A., additional, Baruchel, A., additional, Bertrand, Y., additional, Razzouk, B., additional, Rizzari, C., additional, Smisek, P., additional, Smith, O., additional, Stark, B., additional, and Creutzig, U., additional

Published
2009
Full Text
View/download PDF

34. Prognostic Significance of Time to Relapse in Pediatric AML: Results from the International Randomised Phase III Study Relapsed AML 2001/01

Author

Kaspers, G.J.L., primary, Zimmermann, M., primary, Reinhardt, D., primary, Gibson, B., primary, Tamminga, R., primary, Armendariz, H., primary, Dworzak, M., primary, Ha, S., primary, Hovi, L., primary, Maschan, A., primary, Baruchel, A., primary, Bertrand, Y., primary, Razzouk, B., primary, Rizzari, C., primary, Smisek, P., primary, Smith, O., primary, Stark, B., primary, and Creutzig, U., primary

Published
2008
Full Text
View/download PDF

35. Long-Term Continuing Second Complete Remission (CCR2) despite Allogeneic Stem Cell Transplantation in CR1: Results from the International Randomised Phase III Study Pediatric Relapsed AML 2001/01

Author

Kaspers, G.J.L., primary, Zimmermann, M., primary, Reinhardt, D., primary, Gibson, B., primary, Tamminga, R., primary, Armendariz, H., primary, Dworzak, M., primary, Ha, S., primary, Hovi, L., primary, Maschan, A., primary, Baruchel, A., primary, Bertrand, Y., primary, Razzouk, B., primary, Rizzari, C., primary, Smisek, P., primary, Smith, O., primary, Stark, B., primary, and Creutzig, U., primary

Published
2008
Full Text
View/download PDF

36. Prognostic Significance of Early Treatment Response in Pediatric Relapsed Acute Myeloid Leukemia: Results from the International Study Relapsed AML 2001/01.

Author

Kaspers, Gertjan J., primary, Zimmermann, M., primary, Reinhardt, D., primary, Tamminga, R., primary, Gibson, B., primary, Armendariz, H., primary, Dworzak, M., primary, Ha, S., primary, Hovi, L., primary, Maschan, A., primary, Philippe, N., primary, Razzouk, B., primary, Rizzari, C., primary, Smisek, P., primary, Smith, O., primary, Stark, B., primary, Will, A., primary, and Creutzig, U., primary

Published
2007
Full Text
View/download PDF

39. Outcome of Infants Less Than One Year of Age with Acute Lymphoblastic Leukemia Treated with the Interfant-99 Protocol.

Author

Pieters, Rob, primary, Schrappe, M., additional, de Lorenzo, P., additional, Hann, I., additional, Vora, A., additional, deRossi, G., additional, Biondi, A., additional, Felice, M., additional, Hovi, L., additional, Mechinaud, F., additional, Szczepanski, T., additional, Ferster, A., additional, Janka, G., additional, Rubnitz, J., additional, Silverman, L., additional, Stary, J., additional, Campbell, M., additional, Mann, G., additional, Suppiah, R., additional, and Valsecchi, M., additional

Published
2006
Full Text
View/download PDF

40. Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Report of the International Randomised Phase III Study Relapsed AML 2001/01.

Author

Kaspers, Gertjan J., primary, Zimmermann, M., additional, Fleischhack, G., additional, Tamminga, R., additional, Gibson, Brenda, additional, Armendariz, H., additional, Dworzak, M., additional, Ha, S., additional, Hovi, L., additional, Maschan, A., additional, Philippe, N., additional, Razzouk, Bassem, additional, Rizzari, C., additional, Smisek, P., additional, Smith, Owen, additional, Stark, Batia, additional, Will, A., additional, and Creutzig, Ursula, additional

Published
2006
Full Text
View/download PDF

41. Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Results of the International Randomised Phase III Study “Relapsed AML 2001/01”.

Author

Kaspers, Gertjan J., primary, Zimmermann, M., primary, Fleischhack, G., primary, Tamminga, R., primary, Gibson, B., primary, Armendariz, H., primary, Dworzak, M., primary, Ha, S., primary, Hovi, L., primary, Maschan, A., primary, Philippe, N., primary, Razzouk, B., primary, Rizzari, C., primary, Smisek, P., primary, Smith, O., primary, Stark, B., primary, and Creutzig, U., primary

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results